Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
HUTCHMED (China) Limited (GB:HCM)
LSE:HCM
RESEARCH TOOLSreports
Holding GB:HCM?
Track your performance easily
HCM Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range190.40p - 353.00p
Previous Close281p
Volume30.67K
Average Volume (3M)146.07K
Market Cap
£2.48B
Enterprise Value1.86B
Total Cash (Recent Filing)$886.34M
Total Debt (Recent Filing)$86.13M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Feb 27, 2025EPS Estimate
>-£0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding871,359,720
10 Day Avg. Volume42,371
30 Day Avg. Volume146,070
Standard Deviation0.16
R-Squared0.07
Alpha0.00819
Financial Highlights & Ratios
Price to Book (P/B)67.78
Price to Sales (P/S)3.98
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.55
Enterprise Value/Gross Profit4.09
Enterprise Value/Ebitda-23.11
Forecast
1Y Price Target
397.03pPrice Target Upside41.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
HUTCHMED (China) Limited News
PremiumCompany Announcements
HUTCHMED Expands Cancer Treatment Market with Japan Launch
PremiumCompany Announcements
HUTCHMED China Announces Diverse Board Leadership
PremiumCompany Announcements
HUTCHMED Appoints Experienced Director to BoardPremiumCompany Announcements
HUTCHMED to Present Promising Clinical Data in 2024
PremiumCompany Announcements
HUTCHMED Receives Milestone Payment from TakedaOptions Prices
Currently, No data available
---
Ownership Overview
1.11% Insiders
1.80% Mutual Funds
― Other Institutional Investors
94.81% Public Companies and
Individual Investors
HCM FAQ
What was HUTCHMED (China) Limited’s price range in the past 12 months?
HUTCHMED (China) Limited lowest share price was 190.40p and its highest was 353.00p in the past 12 months.
What is HUTCHMED (China) Limited’s market cap?
Currently, no data Available
When is HUTCHMED (China) Limited’s upcoming earnings report date?
HUTCHMED (China) Limited’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
How were HUTCHMED (China) Limited’s earnings last quarter?
HUTCHMED (China) Limited released its earnings results on Jul 31, 2024. The company reported 0.024p earnings per share for the quarter, beating the consensus estimate of -0.061p by 0.085p.
Is HUTCHMED (China) Limited overvalued?
According to Wall Street analysts HUTCHMED (China) Limited’s price is currently Undervalued.
Does HUTCHMED (China) Limited pay dividends?
HUTCHMED (China) Limited does not currently pay dividends.
What is HUTCHMED (China) Limited’s EPS estimate?
HUTCHMED (China) Limited’s EPS estimate is >-£0.01.
How many shares outstanding does HUTCHMED (China) Limited have?
HUTCHMED (China) Limited has 871,561,950 shares outstanding.
What happened to HUTCHMED (China) Limited’s price movement after its last earnings report?
HUTCHMED (China) Limited reported an EPS of 0.024p in its last earnings report, beating expectations of -0.061p. Following the earnings report the stock price went up 6.383%.
Which hedge fund is a major shareholder of HUTCHMED (China) Limited?
Currently, no hedge funds are holding shares in GB:HCM
---
HUTCHMED (China) Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
397.03p (41.29% Upside)
397.03p (41.29% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.26%
12-Months-Change
Fundamentals
Return on Equity
-5.61%
Trailing 12-Months
Asset Growth
-2.27%
Trailing 12-Months
Company Description
HUTCHMED (China) Limited
Hutchison China Meditech is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.
---
HCM Stock 12 Month Forecast
Average Price Target
397.03p
▲(41.29% Upside)
Technical Analysis
Best Analysts Covering HCM
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+8.08%
reiterated a buy rating 4 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +8.08% per trade.
---